Nordic Diabetic Retinopathy Market Size & Outlook, 2025-2033
Nordic Diabetic Retinopathy Market Insights
- As per Reed Intelligence insights, the Nordic Diabetic Retinopathy Market stood at USD 95.88 Million in 2024 and is anticipated to grow to USD 181.26 Million by 2033.
- The Nordic market is expected to advance at a CAGR of 7.31% from 2026 through 2033.
- In 2024, Proliferative Diabetic Retinopathy accounted for the highest share of the By Type market size.
- During the forecast period, Proliferative Diabetic Retinopathy is set to register the highest growth, making it the most lucrative By Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Nordic contributed 1.05% to the global Diabetic Retinopathy Market size in 2024.
- By 2033, United States is forecasted to remain the largest global market for Diabetic Retinopathy Market.
- In Europe, Germany is projected to capture the leading share of market size by 2033.
- Among Europe markets, Germany is expected to post the fastest growth, reaching USD 914.25 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 95.88 Million |
| Market Size In 2033 | USD 181.26 Million |
| Largest segment | Proliferative Diabetic Retinopathy |
| Units | Revenue in USD Million |
| CAGR | 7.31% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Treatment Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Nordic Diabetic Retinopathy Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | 52.74 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Diabetic Retinopathy Market By Treatment Type 2025-2033 (USD Million)
| By Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-VEGF Drug | XX.x | XX.x | XX.x | 38.93 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Steroid Implants | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Laser Surgeries | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vitrectomy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
